

**Attachment 5**

**NPCR CSS Data Release Policy**

# **National Program of Cancer Registries Cancer Surveillance System (NPCR-CSS)**

## **Data Release Policy for 2009 Data Submission**

---

Policy Revised January 2009

Cancer Surveillance Branch  
Division of Cancer Prevention and Control  
NCCDPHP, CDC, Mailstop K-53  
Atlanta, Georgia 30341-3717  
Phone: 770-488-4783  
E-mail: [cancerinfo@cdc.gov](mailto:cancerinfo@cdc.gov) (specify “NPCR-CSS” in subject line)

## Table of Contents

	Page
Acknowledgement	3
<b>I.</b> Introduction	4
<b>II.</b> Assurance of Confidentiality	4
<b>III.</b> Overview of the Data	5
<b>IV.</b> Requests for State or Local Data and Notification of States	6
<b>V.</b> Public-Use Data Sets	7
<b>A.</b> United States Cancer Statistics ( <i>USCS</i> ) Data Set	8
<b>B.</b> <i>USCS</i> Expanded Data Set	8
<b>C.</b> <i>USCS</i> County Cancer Incidence Data Set	8
<b>D.</b> Public Release Disclosure Statement	8
<b>VI.</b> Restricted-Access Data Set	9
<b>A.</b> State Level Restricted-Access Data Set	9
<b>B.</b> Regional Level Restricted-Access Data Set	9
<b>VII.</b> Emergency and Provisional Data Releases	10
<b>VIII.</b> Data Release Under Controlled Conditions	10
<b>IX.</b> References	11
 <b>Table 1</b> Comparison of NPCR-CSS Data	 12
 <b>Appendices</b>	
Appendix A    NPCR-CSS Scientific Working Group Members NPCR-CSS Small Data Release Working Group	16
Appendix B    NPCR-CSS 308(d) Assurance of Confidentiality	18
Appendix C    NPCR-CSS 308(d) Assurance of Confidentiality Frequently Asked Questions	19
Appendix D    NPCR-CSS Overview of Data Security	23
Appendix E    State and Metropolitan Area Cancer Registries by Federal Funding Source and First Diagnosis Year for Which Cancer Cases Were Reportable to CDC's NPCR or NCI's SEER Program	25
Appendix F    NPCR-CSS Data Sharing Agreement	27
Appendix G    Data Items for Restricted Access Data Sets	29

## **Acknowledgement**

The Cancer Surveillance Branch, Division of Cancer Prevention and Control, NCCDPHP, CDC, wishes to acknowledge and thank the members of the state-based NPCR-CSS Scientific Working Group for their contributions to the concepts included in this document. Since 2005, the members of the Small Data Release Working Group—a subgroup of the Scientific Working Group—played an important role in the review and release of the *USCS* expanded data set on CDC WONDER and the restricted-access data sets. Appendix A lists the members of both working groups.

**National Program of Cancer Registries  
Cancer Surveillance System  
Data Release Policy  
November 2008**

**I. Introduction**

This document describes the format and content of data that the National Program of Cancer Registries' Cancer Surveillance System (NPCR-CSS) will release or share. This multi-year policy updates the December 2007 NPCR-CSS *Data Release Policy*. This policy applies to data submitted to the Centers for Disease Control and Prevention (CDC) for the 2009 data submission and for all future data submissions until a new policy is provided.

The NPCR-CSS Privacy Steward (Mr. Joseph Rogers) will clear all releases of state data, ensuring that the data are released according to the terms of the NPCR-CSS Data Release Policy.

It is possible that, in future years, data release practices or the content and format of released data may vary from those described in these guidelines. Such changes may occur as a result of improvements in the quality of the data, changes in information technology, and evolving data needs. *However, if such variations occur, they will provide comparable protection (or more protection) for patient confidentiality than is described in this policy.* If it is anticipated that any data will be released with *less* protection (as determined by the NPCR-CSS Privacy Steward) for patient confidentiality than is described in this policy, NPCR central registries will be notified and will have ample time to respond before the data are released. This policy will be reviewed annually by the NPCR-CSS Privacy Steward and other appropriate CDC staff members to determine whether revisions are needed. If revisions are needed, NPCR central registries will be notified and allowed to review and comment on the revisions before they become final.

**II. Assurance of Confidentiality**

All data collected and maintained by NPCR-CSS must be managed, presented, published, and released in accordance with strict attention to confidentiality and security, consistent with the general principles and guidelines established by CDC for confidential case data<sup>1-3</sup> and specific restrictions imposed on the NPCR-CSS data (Appendices B, C, and D).<sup>4</sup> Special care is needed even for cancer incidence data that are not directly identifiable because geographic and small cell data may be indirectly identifying when combined with detailed information in case reports or from laboratory, medical records, or linkage with other data files.<sup>5-10</sup>

NPCR-CSS has approval for protection under section 308(d) of the Public Health Services (PHS) Act (42 USC 242m(d)) (Appendices B and C). The 308(d) confidentiality assurance protects identifiable and potentially identifiable information from being used for any purpose other than the purpose for which it was collected unless the person or establishment from which it was obtained has consented to such use. This assurance protects against disclosures under a court order and provides protections that the Privacy Act of 1974 (5 USC 552a) does not. For example, the Privacy Act of 1974 protects individual participants, but the 308(d) confidentiality assurance also protects institutions. Confidentiality protection granted by CDC promises participants and institutions that their data will be shared only with those individuals and institutions listed in the project's consent form or in its specified policies.

### III. Overview of the Data

In 1992, Congress established the National Program of Cancer Registries (NPCR) by enacting the Cancer Registries Amendment Act, Public Law 102-515.<sup>4</sup> The law authorized CDC to provide funds and technical assistance to states and territories to improve or enhance existing cancer registries and to plan for and implement population-based central cancer registries where they did not exist. NPCR's purpose is to assure the availability of more complete local, state, regional, and national cancer incidence data for planning and evaluation of cancer control interventions and for research. NPCR adopted reporting requirements and definitions consistent with the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results Program (SEER);<sup>11,12</sup> required the use of uniform data items and codes and record layouts as defined by consensus of members of the North American Association of Central Cancer Registries (NAACCR);<sup>13</sup> and established standards for data management and data completeness, timeliness, and quality similar to those recommended by NAACCR.<sup>13,14</sup> In 1994, the first 37 states received funding from CDC. Currently, 45 states, the District of Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions are funded by NPCR (hereafter referred to as states) (Appendix E).<sup>15,16</sup> NPCR-funded central registries collect data on patient demographics, primary tumor site, morphology, stage of disease at diagnosis, and first course of treatment. In addition, NPCR central registries conduct follow-up for vital status by linking with state and national death files.

Invasive and *in situ* cancer case reports are submitted to CDC by population-based statewide central cancer registries in all 45 participating states, the District of Columbia, Puerto Rico, and the U.S. Pacific Island Jurisdictions. In each state or territory, state laws and regulations mandate the reporting of cancer cases by facilities and practitioners who diagnose or treat cancer to the state health department or its designee.<sup>4</sup> The central cancer registry receives case reports from facilities and practitioners throughout the state and processes them according to standard data management procedures.<sup>14</sup> Personal identifiers including the patient's name, social security number, and street address are removed prior to the encryption and electronic transmission of these case reports to a contractor acting on behalf of CDC. CDC and the contractor adhere to strict data security procedures when receiving, processing, and managing the data (Appendix D). For more information on the NPCR-CSS data, see the Technical Notes as posted on the *United States Cancer Statistics* Web site (<http://www.cdc.gov/uscs>) which is updated annually. NPCR-CSS received formal approval (protocol #2594) from CDC's Institutional Review Board (IRB) in October 1999. The approval is updated annually. CDC has an Office for Human Research Protections (OHRP)-approved federal-wide assurance of compliance with rules for the protection of human subjects in research ([45 CFR 46](http://45CFR46)) ([http://ohrp.osophs.dhhs.gov/nsearch\\_t.htm](http://ohrp.osophs.dhhs.gov/nsearch_t.htm)).

Central cancer registries and federal agencies routinely publish cancer incidence data between 22 and 25 months after the close of each diagnosis year based on data that meet standards for completeness and quality.<sup>16,17</sup> However, other versions of the same data, based on the data file as it exists at different time periods, are usually available. For example, some central registries have preliminary data available as soon as 12 months after the close of each diagnosis year. Even after the publication of official statistics, central cancer registries (and CDC and NCI) continue to update and re-publish data with new information incorporated. Thus, when cancer incidence data are published it is common practice to document either the data submission date (i.e., when the data were submitted to CDC or NCI) or the date the file was prepared. Changes in central cancer registry incidence data that occur more than 22 to 25 months after the close of a diagnosis

year are likely to be small; however, delays in reporting are more likely to impact certain cancer sites and may be important for some research studies.<sup>18</sup>

#### **IV. Requests for State or Local Data and Notification of States**

The Freedom of Information Act (FOIA) (<http://www.cdc.gov/od/foia/foi/htm>) generally provides that, upon written request from any person, a Federal agency (i.e., CDC) must release any agency record unless that record falls (in whole or part) within one of nine exemptions. FOIA applies to only Federal agencies, and covers only records in the possession and control of those agencies at the time of the FOIA request (except in certain narrow instances involving grantee-held data). Because State-based data becomes a Federal record in CDC's possession, such records are subject to disclosure in response to a FOIA request. The FOIA exemptions that may be available to protect some aspects of State data from public disclosures in response to a FOIA request are:

- 1) Exemption 3, which specifically exempts information from disclosure by statute (in this instance pursuant to an Assurance of Confidentiality under Section 308(d) of the Public Health Service Act), and
- 2) Exemption 6, which exempts from disclosure personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

In general, non-FOIA requests to CDC from the public, the media, and other government agencies for local cancer incidence data are referred to the state health department for a reply. There are three reasons for this: (1) the state health departments can release cancer incidence data in accordance with locally established policies and procedures and consistent with provisions of the 1992 Cancer Registries Act, Public Law 102-515;<sup>4</sup> (2) the relative infrequency of data submission to federal agencies assures that the state health department or its designated central cancer registry will have the most complete, accurate, and up-to-date information; and (3) the central registry may be able to provide more detailed data that can better meet the needs of the requestor. When the request is for data regarding cancer incidence involving more than one state, CDC will refer the requestor to published reports or to NPCR-CSS data sets that are released in accordance with practices described in this document. At this time, it is anticipated that two kinds of data sets will be released: *public-use data sets* and *restricted-access data sets* (see definitions below).

CDC staff members or contractors perform analyses of NPCR program data as needed, including assessment of the completeness, timeliness, and quality of cancer incidence data; and analyses of the cancer burden as needed for meeting national cancer control objectives. Such analyses of state and national data are conducted routinely by federal agencies, including CDC, for programmatic or statistical purposes as needed to achieve the agency's mandate. Publications or presentations describing the quality of the data or the burden of cancer may be one outcome of such analyses. Examples of topics for such analyses are descriptive analyses by racial and ethnic populations for specific cancers and descriptions of cancer incidence trends. In compliance with the 308(d) Assurance of Confidentiality, CDC employees and contractors are required to handle the information in accordance with principles outlined in the CDC Staff Manual on Confidentiality and to follow the specific procedures documented in the NPCR-CSS Confidentiality/Security Statement (Appendices B, C, and D).

In addition to adhering to strict requirements for protecting confidentiality, CDC staff members will notify the state cancer registry in advance whenever they plan to present, publish or release

state-specific information on cancer incidence that have not been previously presented, published, or released. This notification will include, when possible, sending a pre-publication copy of the entire publication or other information to the specific states. When that is not possible (for example if the information is embargoed), the specific state cancer registries will receive a summary of the information before it is published or released. In addition, CDC staff members are required to acknowledge state cancer registries whenever NPCR-CSS data are presented, released, or published by CDC by making available the following (or similar) statement:

These data were provided by cancer registries participating in the National Program of Cancer Registries (NPCR) and submitted to CDC in the (insert submission date) NPCR-Cancer Surveillance System data submission.

## **V. Public-Use Data Sets**

For purposes of this policy, public-use data sets (PUDS) are defined as data sets that are comprised of aggregated data (i.e., not individual case-specific data or microdata) that have been modified as needed, according to accepted procedures, to block breaches of confidentiality and prevent disclosure of the patient's identity or the patient's confidential information.<sup>2, 5-10</sup> A combination of confidentiality protection measures is employed for each PUDS (Table 1). PUDS will not contain information that is identifiable or potentially identifiable according to currently accepted procedures for reducing disclosure risk.<sup>2, 5-10</sup> One of the PUDS is available as a Web-based query system and has a database behind a CDC firewall that is case-specific microdata; however, even for this database users will be able to access only aggregate counts and rates with all confidentiality protections built in. Before each PUDS is finalized, the aggregate values will be analyzed to determine whether there is a need for complementary cell suppression.<sup>2, 5-10</sup> If appropriate, the analysis will include consultation with a statistician with specific expertise in statistical disclosure limitation techniques. Following the analysis, complementary cell suppression will be applied as needed.

There will be no restrictions on access to PUDS. A public release disclosure statement (see page 9) will caution users against inappropriate use of the data or inappropriate disclosure of information. PUDS will be released as delimited ASCII files, a Web-based query system, or possibly through other vehicles (Table 1). States will have an opportunity to review their state's data before each PUDS is released and have adequate time to notify CDC if they identify a problem with the data. As a convenience to NPCR central registries, states may request from CDC a copy of their complete state-specific analytic database that is used to create each PUDS. The following three PUDS are currently being released:

- *United States Cancer Statistics (USCS)* data set,
- *USCS* expanded data set, and
- *USCS* county cancer incidence data set.

All NPCR-CSS PUDS will consist of cancer incidence data selected from the NPCR-CSS analytic database. This is the same database that provides cancer incidence data for the annual publication of *USCS*.<sup>16</sup> Data sources, case definitions, basic registry eligibility criteria in terms of required data completeness and quality, population denominator sources, methods for calculating incidence rates, and the rationale for specific cell suppression thresholds are as described in the Technical Notes for *USCS* unless noted in separate documentation that accompanies the PUDS. Data from NCI's SEER program are included in some, but not all, data releases described in this document. However, based on the underlying principles for coordinated nationwide cancer



control as stated in the CDC and NCI Surveillance Memorandum of Understanding, the goal is to have all data sets include data from both NPCR and SEER.

Separate documentation may accompany each PUDS which will describe its unique features; for example, the data submission date, percentage of the U.S. population covered, diagnosis years and cancer sites included, variables included, any special data quality criteria required for inclusion, and any unique statistical methods employed.

#### **A. *United States Cancer Statistics (USCS) Data Set***

The *USCS* data set contains the same aggregate counts and rates for incidence and mortality published annually (Table 1). The PUDS is an HTML edition of *USCS*. Tables of male and female combined counts and rates are in the HTML edition in addition to the published sex-specific tables. Users can download the data in ASCII, MS Excel and SAS dataset formats for use in other applications.

#### **B. *USCS Expanded Data Set***

The *USCS* expanded data set displays the aggregate counts, rates, and 95% confidence intervals published yearly in the *USCS*, plus additional aggregate values created from the same analytic file containing finer breakdowns of counts and rates based on selected variables (Table 1). This PUDS is available on WONDER (<http://wonder.cdc.gov>), a Web-based query system, that has a database behind a CDC firewall with case-specific microdata; however, users will be able to access only aggregate counts and rates with all confidentiality protections built in. Because this PUDS will present data in more detail than is presented in *USCS*, states will have the option to notify NPCR if they prefer not to have their state data included.

#### **C. *USCS County Cancer Incidence Data Set***

The *USCS* county cancer incidence data set consists of aggregate cancer incidence counts, crude rates, and age-adjusted rates for selected counties in the United States (Table 1). This PUDS is available as an ASCII file. Because this PUDS presents data at a sub-state geographic level, states have the option to notify NPCR if they prefer not to have their county data included. A limited version of this PUDS has been released to a small number of users, including NCI for the State Cancer Profiles project ([www.statecancerprofiles.cancer.gov](http://www.statecancerprofiles.cancer.gov)) and the U.S. Department of Health and Human Services' Women's Health Initiative Project. Future versions may contain more detail about cancer at the county level. Beginning in 2008, CDC will routinely publish county data averaged over five years.

#### **E. Public Release Disclosure Statement**

The following (or similar) public release disclosure statement will be prominently displayed for users of all NPCR-CSS PUDS:

Data Use Restrictions: Read Carefully before Using

**By using these data, you signify your agreement to comply with the following statutorily based requirements.** The National Program of Cancer Registries (NPCR), Centers for Disease Control and Prevention (CDC), has obtained an assurance of confidentiality pursuant to Section 308(d) of the Public Health Service Act, 42 U.S.C. 242m(d). This assurance provides that identifiable or potentially identifiable data collected by the NPCR may be used only for the purpose for which they were obtained unless the person or establishment from which they were obtained has consented to such use. Any effort to determine the identity of any reported cases, or

to use the information for any purpose other than statistical reporting and analysis, is a violation of the assurance. Therefore users will:

- Use the data for statistical reporting and analysis only.
- Make no attempt to learn the identity of any person or establishment included in these data.
- Make no disclosure or other use of the identity of any person or establishment discovered inadvertently, and advise the Associate Director for Science, Office of Science Policy and Technology Transfer, CDC, Mailstop D-50, 1600 Clifton Road, N.E., Atlanta, Georgia, 30333, Phone: 404-639-7240) (or NCI's SEER Program if SEER data) and the relevant state or metropolitan area cancer registry, of any such discovery.

## **VI. Restricted-Access Data Sets**

For purposes of this policy, restricted-access data sets (RADS) are defined as versions of the full NPCR-CSS analytic data set, either aggregated data or microdata (i.e., individual case-specific data), that have been modified as needed to minimize (but may not remove entirely) the potential for disclosure of confidential information. RADS will not contain personal identifiers such as a patient's name, street address, or social security number as this information is not transmitted by central cancer registries to CDC as part of their annual data submission. However, they may contain information that is potentially identifiable especially when linked with other data sets, such as the occurrence of a rare cancer in a person of a certain age or racial or ethnic group. The following two RADS are described:

- Regional level restricted-access data set (rRADS)
- State level restricted-access data set (sRADS)

The list of the variables included in these RADS is in Appendix G.

Because restricted-access data sets may potentially contain identifiable information, states will have the option to notify NPCR if they prefer not to have their data included in either or both of these restricted access data sets.

### **A. Regional Level Restricted-Access Data Set (rRADS)**

The rRADS will be released after the requestor signs a detailed data sharing agreement and provides a description of the proposed project. The intent of the regional-level dataset is to provide access to individual case-specific data with reduced potential for disclosure of confidential information and correspondingly less oversight from CDC. The rRADS is similar to the sRADS, but with reduced geographic specificity and fewer data items.

Reducing geographic specificity is an effective way to reduce the potential for disclosure of confidential information.

### **B. State Level Restricted-Access Data Set (sRADS)**

The sRADS will be released only after CDC authenticates the requestor's identity and the requestor either signs a detailed data sharing agreement or signs a less detailed data sharing agreement and submits confirmation of IRB approval by an institution with appropriate assurance from the U.S. Department of Health and Human Services' Office for Human Research Protections ([http://ohrp.osophs.dhhs.gov/nsearch\\_t.htm](http://ohrp.osophs.dhhs.gov/nsearch_t.htm)).

To define and develop the RADS, CDC staff members are working collaboratively with a subset (Small Data Release Working Group) of the NPCR-CSS Scientific Working Group. The resources needed for preparation, data quality testing, releasing, logging<sup>2</sup> and monitoring the release of restricted data sets have been and will continue to be substantial. Thus, release of these data sets will be phased in over several years. The sRADS was first made available to ACS, NCI

and members of the Small Data Release Working Group starting in November 2005. In November 2006, the sRADS was made available to ACS, NCI, and all NPCR central registries. In future years, the sRADS will be available to other researchers who meet the criteria jointly established by CDC and NPCR central registries. These RADS are currently available as an ASCII file. User documentation including a data dictionary for every diagnosis year since 1994 are available.<sup>13</sup> Detailed data sharing agreements, and procedures for user authentication and for logging and monitoring of data releases, have been developed. The recently completed *CDC/ATSDR/CSTE Data Release Guidelines for Re-Release of State Data* described in detail the recommended contents of such a data sharing agreement and provided guidance for user authentication and logging and monitoring of data releases.<sup>2</sup> CDC staff members and partners who worked together to plan for the release of these data sets have reviewed these CDC recommendations and other relevant materials and have developed data sharing agreements that meet the requirements of federal agencies. A similar approach has been used for developing methods for user authentication, logging of data releases, and compliance monitoring.

## **VII. Emergency and Provisional Data Releases**

It is not anticipated that CDC will ever need to release NPCR-CSS data before the files have been modified as needed to protect confidentiality as described in this policy. This is prohibited by the 308(d) Assurance of Confidentiality (Appendices B and C).

Provisional data and draft data tables will be shared with CDC employees and contractors, NPCR central registries, and other partners as needed in order to facilitate quality reviews of the data. When appropriate, individuals who participate in such reviews will sign a data use agreement before accessing the data or tables.

## **VIII. Data Release under Controlled Conditions**

CDC-wide policy stipulates that a CDC program may consider release of data that cannot be released as either a PUDS or a RADS under certain controlled conditions.<sup>1</sup> These controlled conditions may include a CDC-controlled data center such as the data center established at NCHS (<http://www.cdc.gov/nchs/r&d/rdc.htm>) or through special licensing. NPCR-CSS data will not be released under these controlled conditions while this policy is in place. Release of data under controlled conditions will be considered as part of discussions with partners toward development of RADS, and a determination will be made as to whether such releases of data will be considered in the future for NPCR-CSS data.

## IX. References

1. Centers for Disease Control and Prevention. *CDC/ATSDR Policy on Releasing and Sharing Data*. Atlanta: Centers for Disease Control and Prevention; 2003. Available at <http://www.cdc.gov/od/foia/policies/sharing.htm>.
2. Centers for Disease Control and Prevention. *CDC/ATSDR/CSTE Data Release Guidelines for Re-Release of State Data*. Atlanta: Centers for Disease Control and Prevention; 2003 (available upon request).
3. Centers for Disease Control and Prevention. *CDC Staff Manual on Confidentiality*. Atlanta: Centers for Disease Control and Prevention; 1984 and National Center for Health Statistics. *NCHS Staff Manual on Confidentiality*. Hyattsville MD: National Center for Health Statistics; 1999.
4. Cancer Registries Amendment Act, Public Law 102-515, Stat. 3312 (October 22, 1992). Available at <http://www.cdc.gov/cancer/npcr/npcrpdfs/publaw.pdf>.
5. American Statistical Association. Privacy, Confidentiality, and Data Security Web Site. Alexandria, VA: American Statistical Association; 2005. Available at <http://www.amstat.org/comm/cmtepc/index.cfm>.
6. Doyle P, Lane JI, Theeuwes JM, Zayatz LM (eds). *Confidentiality, Disclosure, and Data Access: Theory and Practical Application for Statistical Agencies*. Amsterdam: Elsevier Science BV; 2001.
7. Federal Committee on Statistical Methodology. *Checklist on Disclosure Potential of Proposed Data Releases*. Available at <http://www.fcsm.gov/committees/cdac/cdac.html>.
8. Federal Committee on Statistical Methodology. *Report on Statistical Disclosure Limitation Methodology*. (Statistical Working Paper 22). Washington (DC): Office of Management and Budget; 1994. Available at <http://www.fcsm.gov/working-papers/spwp22.html>.
9. McLaughlin C. Confidentiality protection in publicly released central cancer registry data. *Journal of Registry Management* 2002; 29(3):84-88.
10. Stoto M. *Statistical Issues in Interactive Web-Based Public Health Data Dissemination Systems*. Draft report prepared for the National Association of Public Health Statistics and Information Systems, Rand Corporation; September 2002.
11. Surveillance, Epidemiology, and End Results Program. *The SEER Program Code Manual*. 3rd ed. Bethesda (MD): National Cancer Institute, 1998.
12. Percy C, Van Holten V, Muir C (eds). *International Classification of Diseases for Oncology, 2nd edition*. Geneva, Switzerland: World Health Organization; 1990.
13. Hultstrom D, editor. *Standards for Cancer Registries, vol. II: Data Standards and Data Dictionary*, version 9.1, 6th ed. Springfield (IL): North American Association of Central Cancer Registries; 2001.
14. North American Association of Central Cancer Registries. *Standards for Cancer Registries, vol. III: Standards for Completeness, Quality, Analysis, and Management of Data*. Springfield (IL): North American Association of Central Cancer Registries; 2000.
15. Hutton MD, Simpson, LD, Miller DS, Weir HK, McDavid K, Hall HI, Progress toward nationwide cancer surveillance: an evaluation of the National Program of Cancer Registries, 1994-1999. *Journal of Registry Management* 2001;28(3):113-120.
16. U.S. Cancer Statistics Working Group. *United States Cancer Statistics: 2004 Incidence and Mortality, Technical Notes*. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007.
17. Method for estimating case completeness is available in: Wu XC, Hotes JL, Fulton PJ, Cormier M, Correa CN, McLaughlin CC, Kosary C, Howe HL, Chen VW, editors. *Cancer in North America, 1995-1999, vol. I: Incidence*. Springfield, IL: North American Association of Central Cancer Registries; 2002. Available at <http://www.naaccr.org/Stats/CINAPubs.html>.
18. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. *Journal of the National Cancer Institute* 2002;94(20):1537-45.

**Table 1. Comparison of the National Program of Cancer Registries –Cancer Surveillance System Data Sets**

<b>Overview</b>					
	<b>Public-Use Data Sets (PUDS)</b>			<b>Restricted-Access Data Sets (RADS)</b>	
	<i>USCS</i>	<i>USCS Expanded</i>	<i>USCS County</i>	<b>Regional Level</b>	<b>State Level</b>
<b>Format</b>	Database of aggregate counts and rates, with text documentation	Database of aggregate counts and rates, with text documentation. The database behind the CDC firewall is case-specific microdata.	Database of aggregate counts and rates, with text documentation	Database of individual record level data	Database of individual record level data
<b>Mode of Access</b>	Web-based query system with downloadable ASCII files, MS Excel files, and SAS datasets	Web-based query system	Flat ASCII file and Web-based query system and separate brief text documentation	Flat ASCII file or SEER*Stat file	Flat ASCII file or SEER*Stat file
<b>Web Address or Contact Information</b>	<i>USCS</i> website ( <a href="http://www.cdc.gov/uscs">www.cdc.gov/uscs</a> )	CDC Wonder ( <a href="http://wonder.cdc.gov">http://wonder.cdc.gov</a> )	Request from <a href="mailto:cancerinfo@cdc.gov">cancerinfo@cdc.gov</a> (specify “USCS County” in subject line)	Request from <a href="mailto:cancerinfo@cdc.gov">cancerinfo@cdc.gov</a> (specify “Regional RADS” in subject line)	Request from <a href="mailto:cancerinfo@cdc.gov">cancerinfo@cdc.gov</a> (specify “State RADS” in subject line)
<b>Contains Potentially Identifiable Information</b>	No		No	Yes	Yes
<b>Registry Eligibility Criteria for Data Completeness and Quality</b>	USCS publication criteria		USCS publication criteria; data meet criteria for unknown county	USCS publication criteria	USCS publication criteria
<b>When Available</b>	Updated 2009		Updated 2009	2009	Updated 2009

**Table 1. Comparison of the National Program of Cancer Registries –Cancer Surveillance System Data Sets, *continued***

<b>Cases Included</b>					
	<b>Public-Use Data Sets (PUDS)</b>			<b>Restricted-Access Data Sets (RADS)</b>	
	<i>USCS</i>	<i>USCS Expanded</i>	<i>USCS County</i>	<b>Regional Level</b>	<b>State Level</b>
<b>States/Territories</b>	NPCR and SEER states that meet eligibility criteria		NPCR states that meet eligibility criteria*	NPCR states that meet eligibility criteria*	NPCR states that meet eligibility criteria*
<b>Diagnosis Years</b>	Single year of data from 1999-2006; combined years of data from 2002-2006	Single year of data from 1999-2006	Aggregated years of data from 2002-2006	Single year of data from 1999-2006	Single year of data from 1999-2006
<b>Cancer Sites</b>	All reportable invasive cancers; <i>in situ</i> female breast, and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)		All reportable cancer sites combined; female breast; <i>in situ</i> female breast; cervix uteri; colon and rectum; lung and bronchus; melanoma; bladder; prostate; oral cavity and pharynx; brain and other nervous system; thyroid; kidney; stomach; ovary; corpus and uterus, NOS; leukemias; non-Hodgkin lymphoma, liver and intrahepatic bile duct, pancreas, esophagus, and childhood cancers	All reportable invasive and <i>in situ</i> cancers and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)	All reportable invasive and <i>in situ</i> cancers and benign and borderline primary intracranial and central nervous system tumors (diagnosis year 2004)

\* Future plans may include the addition of SEER data similar to the *USCS* data set.

**Table 1. Comparison of the National Program of Cancer Registries –Cancer Surveillance System Data Sets, *continued***

<b>Variables Included</b>					
	<b>Public-Use Data Sets (PUDS)</b>			<b>Restricted-Access Data Sets (RADS)</b>	
	<i>USCS</i>	<i>USCS Expanded</i>	<i>USCS County</i>	<b>Regional Level</b>	<b>State Level</b>
<b>Geographic Levels</b>	All areas combined; U.S. census region and division; NPCR and SEER state or territory; SEER metropolitan area	All areas combined; NPCR and SEER state or territory; MSA for cities of 500,000 or more* (additional levels may be added in 2008)**	NPCR state; county*	United States Census Region (and Division**)	NPCR state or territory*
<b>Race</b>	All races combined; white; black; Asian/Pacific Islander; American Indian/Alaska Native		All races combined; white; black; American Indian/Alaska Native; Asian/Pacific Islander (with appropriate 50,000 population suppression and state permission for AI/AN and A/PI)	All races reported	All races reported
<b>Ethnicity (Hispanic)</b>	Yes		Yes for State Profiles only (with state permission)	Yes	Yes
<b>Age Groups</b>	All ages combined and standard 5 year age groups for adults and <15 and <20 for childhood cancers	All ages combined and standard 5-year age groups that can be combined by the user.	Childhood cancers: <15 and <20; all other cancers: <50, 50-64, 65+	Standard 19 age groups	Standard 5-year age groups and individual ages (Month and day of birth are not provided for confidentiality reasons. If the age at diagnosis over 99, then grouped into one category. Year of birth is also grouped.)
<b>Summary Stage</b>	No		No	Yes	Yes
<b>Histology</b>	International Classification of Childhood Cancers, Third Revision (all geographic areas combined) Mesothelioma (national and state level) Kaposi Sarcoma (national and state level) Consensus Conf on Cancer Registration of Brain and CNS Tumors (all areas only)		No	Yes	Yes

\* Future plans may include the addition of SEER data similar to the *USCS* data set.

\*\* Pending further data quality investigation and discussion with the NPCR-CSS Scientific Working Group.

**Table 1. Comparison of the National Program of Cancer Registries –Cancer Surveillance System Data Sets, *continued***

<b>Confidentiality Protection/Disclosure Limitation Measures Employed</b>					
	<b>Public-Use Data Sets (PUDS)</b>			<b>Restricted-Access Data Sets (RADS)</b>	
	<i>USCS</i>	<i>USCS Expanded</i>	<i>USCS County</i>	<b>Regional Level</b>	<b>State Level</b>
<b>Direct Identifiers?</b>	No		No	Yes	Yes
<b>Aggregation</b>	Yes		Yes	No	No
<b>Limited Number of Variables</b>	Yes		Yes	Yes	Yes
<b>Grouping/Collapsing of Variables or Response Codes</b>	Yes		No	Yes	Yes
(1) <b>Average Annual Counts Rounded to the Nearest Whole Number</b> (2) <b>Average Annual Rates</b> (3) <b>Annual averages are based on at least 5 years of data</b>	No		Yes	No	No
<b>Cell Suppression</b>	Yes Counts and rates: count of less than 16		Yes Counts and rates: 5 year total count of less than 16	No	No
<b>Complementary Cell Suppression</b>	As needed		As needed	No	No
<b>Public Release Disclosure Statement</b>	Yes		Yes	Yes	Yes
<b>Data Sharing Agreement and/or IRB Approval</b>	No		No	Yes	Yes
<b>User Authentication</b>	No		No	Yes	Yes
<b>Logging and Monitoring</b>	Limited		Limited	Yes	



**NPCR-CSS Scientific Working Group Members**

Mark E. Allen, MS, California Cancer Registry  
Janet Bates, MD, MPH, California Cancer Registry  
Sally Bushhouse, DVM, PhD, Minnesota Cancer Surveillance System  
Vivien W. Chen, PhD, Louisiana Tumor Registry  
Susan T. Gershman, MS, MPH, PhD, CTR, Massachusetts Cancer Registry  
Georgette G. Haydu, MS, Ohio Cancer Incidence Surveillance System  
Jeannette Jackson-Thompson, PhD, MSPH, Missouri Cancer Registry  
Alison T. Johnson, CTR, Vermont Cancer Registry  
Amy Kahn, MS, CTR, New York State Cancer Registry  
Karen L. Knight, MS, North Carolina Central Cancer Registry  
Sue Min Lai, PhD, MS, MBA, Kansas Cancer Registry  
Melinda Lehnherr, RN, Illinois State Cancer Registry  
Jill A. MacKinnon, CTR, Florida Cancer Data System  
Fangchao Ma, MD, MPH, PhD, Illinois State Cancer Registry  
Howard J. Martin, PhD, Virginia Cancer Registry  
Xiaoling Niu, MS, New Jersey State Cancer Registry  
Emily Reed, CTR, Kentucky Cancer Registry  
Maria J. Schymura, PhD, New York State Cancer Registry  
Tiefu Shen, MD, PhD, Illinois State Cancer Registry  
Laura Stephenson, BA, Wisconsin Cancer Reporting System  
Cheryll C. Thomas, MSPH, Centers for Disease Control and Prevention  
Thomas C. Tucker, PhD, MPH, Kentucky Cancer Registry  
Hannah Weir, PhD, Centers for Disease Control and Prevention  
Melanie Williams, PhD, Texas Cancer Registry  
Reda J. Wilson, MPH, CTR, Centers for Disease Control and Prevention  
Brian D. Wright, BS, Pennsylvania Cancer Registry  
Xiao Cheng Wu, MD, MPH, CTR, Louisiana Tumor Registry

**NPCR-CSS Small Data Release Working Group**

Mark E. Allen, MS, California Cancer Registry  
Pamela Agovino, MPH, New Jersey State Cancer Registry  
Patricia Andrews, MPH, CTR, Louisiana Tumor Registry  
Vivian W. Chen, PhD, Louisiana Tumor Registry  
Georgette G. Haydu, MS, Ohio Cancer Incidence Surveillance System  
Amy Kahn, MS, CTR, New York State Cancer Registry  
Karen L. Knight, MS, North Carolina Central Cancer Registry  
Sue Min Lai, PhD, MS, MBA, Kansas Cancer Registry  
Jill A. MacKinnon, CTR, Florida Cancer Data System  
Xiaoling Niu, MS, New Jersey State Cancer Registry  
Maria J. Schymura, PhD, New York State Cancer Registry  
Cheryll C. Thomas, MSPH, Centers for Disease Control and Prevention  
Jeannette Jackson-Thompson, PhD, MSPH, Missouri Cancer Registry  
Reda J. Wilson, MPH, CTR, Centers for Disease Control and Prevention

## **National Program of Cancer Registries Cancer Surveillance System 308(d) Assurance of Confidentiality Statement**

A surveillance system of population-based cancer incidence data received from cooperative agreement holders for the National Program of Cancer Registries is being conducted by the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) of the Centers for Disease Control and Prevention (CDC), an agency of the United States Department of Health and Human Services, and Macro International Inc., a contractor of the CDC. The information to be received by the CDC is a subset of a standard set of data items that the State central cancer registry routinely receives from hospitals, pathology labs, clinics and private physicians on all cancer patients diagnosed in the state. This information includes patient demographics and cancer diagnosis and treatment data. Once a year in January, CDC will request cumulative data from central cancer registries. The variables reported to CDC may vary from year to year. The cancer registries maintain these data permanently in longitudinal databases that are used for public health surveillance, program planning and evaluation, and research. CDC will update its longitudinal database each year with data received from the states. These data are used by CDC scientists for routine cancer surveillance, program planning and evaluation, and to provide data for research. NCCDPHP, recognizing the sensitivity of the data being furnished by the States, has applied for and obtained an Assurance of Confidentiality to provide a greater level of protection for the data while at CDC and at the contractor site.

Information received by CDC or its contractors as part of this surveillance system that could lead to direct or indirect identification of cancer patients is collected and maintained at CDC under Section 306 of the Public Health Service (PHS) Act (42 USC 242k) with an assurance that it will be held in strict confidence in accordance with Section 308(d) of the PHS Act (42 USC 242m). It will be used only for purposes stated in this Assurance and will not otherwise be disclosed or released, even following the death of cancer patients in this surveillance system.

Information collected by the CDC will be used without personal identifiers for publication in statistical and analytic summaries and for release in restricted release datasets for research. Information that could lead to direct or indirect identification of cancer patients will not be made available to any group or individual. In particular, such information will not be disclosed to: insurance companies; any party involved in civil, criminal, or administrative litigation; agencies of Federal, State or local government; or any other member of the public.

Collected information that could lead to direct or indirect identification of cancer patients will be kept confidential and, aside from NCCDPHP employees, their contractors, and qualified researchers, no one will be allowed to see or have access to the information. CDC employees and contractors will be required to handle the information in accordance with principles outlined in the CDC Staff Manual on Confidentiality and to follow the specific procedures documented in the Confidentiality Security Statement for this project. Qualified researchers and organizations (e.g., the North American Association of Central Cancer Registries, the American Cancer Society, the National Cancer Institute) will be required to sign a detailed data release agreement to have access to restricted release data.

**National Program of Cancer Registries Cancer Surveillance System  
308(d) Assurance of Confidentiality  
Frequently Asked Questions**

***Background***

The Centers for Disease Control and Prevention (CDC) is responsible for public health surveillance in the United States. CDC collects, compiles, and publishes a large volume of personal, medical, epidemiologic, and statistical data. The success of CDC's operations depends, in part, on the agency's ability to protect the confidentiality of these data. While it is a matter of principle for CDC to guard sensitive information, and federal statutes such as the Privacy Act provide a degree of protection for personally identifiable data, the Public Health Service Act, Section 308(d) enables CDC to provide the highest level of confidentiality protection for sensitive and mission-significant research and surveillance data.

CDC received a formal delegation of authority from the National Center for Health Statistics (then a separate agency) to grant 308(d) confidentiality protection in 1983. Section 308(d) of the Public Health Service Act (42 U.S.C. 242 m(d)) ensures the confidentiality of data collected under Sections 304 and 306 of the Public Health Service Act. These special legislative authorities were the provisions under which NCHS collects and safeguards most of its survey data, along with the mortality data within the National Death Index. CDC was required to establish a stringent application process, and continues to use the authority sparingly. The agency has granted confidentiality assurances to projects deemed significant to CDC's mission, such as surveillance of hospital infections, AIDS and HIV infections, pregnancy related mortality, and congenital defects. Fewer than fifty projects have received 308(d) protection since CDC received this authority, and currently there are only approximately 25 active projects with 308(d) confidentiality assurances. As a testament of the importance of this project to the mission of CDC, the National Program of Cancer Registries (NPCR) has been afforded this special data protection.

**1. What is stated in Public Health Service Act, Section 308(d)?**

The first clause of Section 308(d) states that CDC must explain the purpose for collecting data to persons or agencies supplying information, and it guarantees that CDC will be limited to those specified uses unless an additional consent is obtained. Moreover, the information obtained may be used only by staff of CDC, or its contractors, in the pursuit of such stated purposes. The second clause states that CDC may never release identifiable information without the advance, explicit approval of the person or establishment supplying the information or by the person or establishment described in the information.

**2. What process did NPCR undertake to obtain 308(d) confidentiality protection?**

NPCR staff worked with the CDC Office of General Counsel and the CDC Confidentiality and Privacy Officer to prepare the application for the NPCR Cancer Surveillance System (CSS)

project. The application contained the following four components:

- a. A Justification Statement summarizing the NPCR-CSS project's programmatic purpose, the type of data to be collected, and the uses to be made of the information. This statement also included an assurance that a) the requested data would not be furnished without the guarantee of a confidentiality assurance, b) confidentiality assurance is important to protect the individuals described in the data and to reassure the institutions submitting data, c) the information cannot reliably be obtained from other sources, d) the information is essential to the project's success, e) granting the confidentiality assurance would not prohibit CDC from fulfilling its responsibilities, and f) the advantages of assuring confidentiality outweigh the disadvantages.
- b. An Assurance of Confidentiality Statement delineating anticipated data uses and those with whom identifiable data would be shared, along with general advisements regarding the confidentiality protection.
- c. A Confidentiality Security Statement detailing the stringent safeguarding measures in place to ensure that the promise of confidentiality would not be jeopardized by practices of staff handling the data.
- d. An IRB Review Status Statement verifying NPCR-CSS's exemption from CDC Institutional Review Board (IRB) approval. (The Human Subjects Administrator at the National Center for Chronic Disease Prevention and Health Promotion determined that NPCR-CSS activities are routine surveillance and not research on human subjects. Therefore, protocol review by CDC IRB was deemed not necessary.)

The application was submitted to the CDC Confidentiality Officer for review and modification, prepared for presentation to the CDC Confidentiality Review Group (CRG), and in May 2000 NPCR received 308(d) confidentiality protection approval for NPCR-CSS data, including authorization for retroactive confidentiality protection beginning with diagnosis year 1995. NPCR must file for continuation every five years to maintain the assurance. In 2006, NPCR filed and received approval for continuation.

### **3. What makes 308(d) confidentiality assurance the best protection for NPCR-CSS data?**

The 308(d) confidentiality assurance is the only confidentiality protection that covers routine surveillance activities, such as those conducted by NPCR-CSS. The assurance specifies that data protected by 308(d) may be used only for statistical or epidemiological purposes and not released further in identifiable form without consent. Another exclusive advantage of 308(d) is that it also protects indirectly identifiable data. Operationally, this means that NPCR may never release a directly identifiable variable (e.g., social security number) or any combination of variables that could be used to indirectly identify an individual. Finally, 308(d) provides protection for information on both living and deceased individuals.

### **4. Are there any disadvantages to individuals or institutions protected by the 308(d) confidentiality assurances?**

A 308(d) confidentiality assurance does not pose a disadvantage for individuals or institutions

submitting data to CDC. In fact, 308(d) provides an added benefit because it prevents CDC from freely releasing data to researchers and any other persons or entities that could request access to the data. With the confidentiality assurance protecting NPCR-CSS data, NPCR staff members are prohibited from sharing data except for the purposes stated at the time of data collection, unless consent from those provided the assurance is obtained.

**5. Does NPCR’s 308(d) confidentiality assurance protect the data from subpoena and Freedom of Information Act (FOIA) requests?**

The 308(d) assurance is the strongest protection against compulsory legal disclosure that CDC can offer. Although CDC receives Freedom of Information Act (FOIA) requests, the FOIA (b)(6) exemption enables CDC to withhold sensitive, individually identified data that would constitute a “clearly unwarranted invasion of personal privacy.” It is CDC’s firm position that all projects covered by a 308(d) confidentiality assurance, including NPCR-CSS, meet this exemption.

**6. Has a case involving 308(d) been tested in court?**

Yes. CDC’s ability to protect data submitted to the agency was upheld in court. The case involved a National Institute for Occupational Safety and Health project collecting death certificate information, which is widely accepted as the least sensitive data protected by 308(d). The court’s ruling in favor of the non-release of these data establishes an effective precedent for restricting access to more sensitive data, such as that collected by a cancer registry.

**7. How long are confidential data submitted to NPCR-CSS protected?**

NPCR-CSS data are covered by the 308(d) confidentiality assurance forever. Individual records in the NPCR-CSS surveillance system are protected even following the death of the cancer patients.

**8. Will NPCR release CSS data to persons or agencies outside of CDC?**

An assurance of confidentiality protects NPCR-CSS data held at CDC and by its contractor, Macro International, Inc. Data that are released to external researchers are done so in accordance with the Data Use Agreement (copy attached) prohibiting attempts to identify subjects within the record system. The 308(d) confidentiality protection does not go with the data, and any data released to qualified researchers by CDC are subject to the limits of any coverage afforded by the requesting agency. However, it is important to note that NPCR’s confidentiality assurance prohibits the release of any data that are directly or indirectly identifiable. Therefore, CDC would not release highly sensitive NPCR-CSS data. Under the 308(d), NPCR is permitted to release NPCR-CSS data to qualified researchers and organizations, such as the North American Association of Central Cancer Registries (NAACCR), the American Cancer Society (ACS), and the National Cancer Institute (NCI). This is so because these entities were specifically mentioned in the NPCR-CSS confidentiality assurance as anticipated recipients of identifiable data. Prior to the restricted release of NPCR-CSS data, a detailed data use agreement must be

signed by the requesting party. Information that could lead to the identification of cancer patients, through either direct or indirect methods, cannot be made available to any other group or individual. In particular, NPCR cannot disclose information to insurance companies; any party involved in civil, criminal, or administrative litigation; agencies of federal, state or local government; or any other member of the public.

**9. Are there penalties for violating the confidentiality assurance?**

NPCR employees and contractors at Macro International, Inc. working on the NPCR-CSS project may be subject to fine, imprisonment, and termination of employment for unauthorized disclosure of confidential information. To assure that all NPCR employees are aware of their responsibilities to maintain and protect NPCR-CSS records and the penalties for failing to comply, CDC employees must read and sign a data use agreement. Contract employees at Macro International, Inc. with access to NPCR-CSS data are required to sign a Confidentiality Agreement.

**National Program of Cancer Registries Cancer Surveillance System  
Overview of Data Security**

The NPCR-CSS project data reside on a dedicated server at Macro International (thereafter “Macro”). To ensure the security and confidentiality of project data, the following provisions have been incorporated into the Macro NPCR-CSS Security Plan in accordance with the requirements of the Assurance of Confidentiality.

The NPCR-CSS server is housed in a secure facility at Macro’s Bethesda office with a guard on duty in the lobby 24 hours a day. Elevator and stairwell access is controlled by card key. The server resides on its own local area network (LAN) behind Macro’s firewall.

- Access to the NPCR-CSS server is limited to authorized Macro project staff (see below). It is password protected on its own security domain. No one, including nonproject staff at Macro, is allowed access to the NPCR-CSS data.
- All Macro project staff must sign a confidentiality agreement before passwords and keys are assigned. All staff must pass background checks appropriate to their responsibilities for a public trust position.
- NPCR-CSS data that are submitted electronically are encrypted during transmission from the States. They arrive on a document server behind Macro’s firewall. Each State has its own directory location so that no State has access to another State’s data. The data are moved automatically from the document server to the NPCR-CSS server.
- Receipt and processing logs are maintained to document data receipt, file processing, and report production. All reports and electronic storage media containing NPCR-CSS data are stored under lock and key when not in use and will be destroyed when no longer needed.
- A comprehensive security plan has been developed by Macro’s security team. The security team consists of Donald McMaster, Business Steward; Kevin Zhang, Project Director; Leo Shen, Data Manager and Security Officer; David Radune, Database Administrator; and Gretchen Stanton, LAN and WAN Security Steward. All project staff receive annual security awareness training covering security procedures. The Macro project security team oversees operations to prevent unauthorized disclosure of the NPCR-CSS data.
- Periodic (currently quarterly, but no less than once a year) review and update of Macro security processes will be conducted to adjust for rapid changes in computer technology and to incorporate advances in security approaches. The security plan will be amended as needed to maintain the continued security and confidentiality of NPCR-CSS data.



**Macro  
Authorized Project Staff**

<b>Staff Member</b>	<b>Position</b>
Donald McMaster, M.B.A., M.S.	Business Steward
Kevin Zhang, Ph.D.	Project Director
Leo Shen, M.B.A.	Deputy Director/Security Officer
David Radune, B.S.	Development Manager/Database Administrator
Gretchen Stanton, M.S.	LAN and WAN Security Steward
Qiming He, Ph.D.	QA Manager/Sr. Programmer Analyst
Yuan Ren, Ph.D.	Data and Statistical Manager/Sr. Statistical Programmer
Jonathan Stanger, M.P.A.	SQL Programmer
Phillip Schaeffer, M.S.	Sr. SAS Programmer
Jagruti Rana, M.S.	Sr. Developer
Shaobin Xu, M.S.	Programmer Analyst
Shailendra Bhavsa, B.S.	Programmer Analyst

**State, Metropolitan Area, and Territory Cancer Registries by Federal Funding Source, and  
First Diagnosis Year\* for Which Cancer Cases Were Reportable to CDC's NPCR or NCI's  
SEER Program**

<b>State, Metropolitan Area, or Territory</b>	<b>First Diagnosis Year for Which Cancer Cases Were Reportable to NPCR or SEER*</b>	<b>Federal Funding Source</b>
Alabama	1996	NPCR
Alaska	1996	NPCR
Arizona	1995	NPCR
Arkansas	1996	NPCR
California	1995/2000	NPCR/SEER
Los Angeles	1992	SEER
San Francisco-Oakland	1973	SEER
San Jose-Monterey	1992	SEER
Colorado	1995	NPCR
Connecticut	1973	SEER
Delaware	1997	NPCR
District of Columbia	1996	NPCR
Florida	1995	NPCR
Georgia	1995	NPCR
Atlanta	1975	SEER
Hawaii	1973	SEER
Idaho	1995	NPCR
Illinois	1995	NPCR
Indiana	1995	NPCR
Iowa	1973	SEER
Kansas	1995	NPCR
Kentucky	1995/2000	NPCR/SEER
Louisiana	1995/2000	NPCR/SEER
Maine	1995	NPCR
Maryland	1996	NPCR
Massachusetts	1995	NPCR
Michigan	1995	NPCR
Detroit	1973	SEER
Minnesota	1995	NPCR
Mississippi	1996	NPCR
Missouri	1996	NPCR
Montana	1995	NPCR

<b>State, Metropolitan Area, or Territory</b>	<b>First Diagnosis Year for Which Cancer Cases Were Reportable to NPCR or SEER*</b>	<b>Federal Funding Source</b>
Nebraska	1995	NPCR
Nevada	1995	NPCR
New Hampshire	1995	NPCR
New Jersey	1995/2000	NPCR/SEER
New Mexico	1973	SEER
New York	1996	NPCR
North Carolina	1995	NPCR
North Dakota	1997	NPCR
Ohio	1996	NPCR
Oklahoma	1997	NPCR
Oregon	1996	NPCR
Pennsylvania	1995	NPCR
Puerto Rico	1998	NPCR
Rhode Island	1995	NPCR
South Carolina	1996	NPCR
South Dakota	2000	NPCR
Tennessee	1999	NPCR
Texas	1995	NPCR
United States Pacific Island Jurisdictions	Planning	NPCR
Utah	1973	SEER
Vermont	1996	NPCR
Virginia	1996	NPCR
Washington	1995	NPCR
Seattle-Puget Sound	1974	SEER
West Virginia	1995	NPCR
Wisconsin	1995	NPCR
Wyoming	1996	NPCR

\* Diagnosis year is the year during which a reported cancer case was first diagnosed.

CDC = Centers for Disease Control and Prevention

NCI = National Cancer Institute

NPCR = National Program of Cancer Registries

SEER = Surveillance, Epidemiology, and End Results

**National Program of Cancer Registries  
Cancer Surveillance System  
Data Sharing Agreement**

It is of the utmost importance to insure the confidentiality of individuals diagnosed with cancer when information about their cancer is entered into a data base for the purpose of establishing a research resource. In order to protect this data, CDC has obtained an Assurance of Confidentiality under Section 308(d) of the Public Health Service Act (42 U.S.C. 242m(d)), which provides that this data can only be used for the purpose for which it was obtained. In utilizing data on such individuals for research purposes, it is absolutely necessary to insure, to the extent possible, that uses of such data will be limited to research; any effort to determine the identity of any reported cases, or to use the information for any purpose other than for health statistical reporting and analysis, would be prosecuted to the full extent of the law.

The Division of Cancer Prevention and Control (DCPC) does all it can to assure that the identity of data subjects cannot be disclosed. All direct identifiers, as well as characteristics that might lead to identifications, are omitted from the data set. Nevertheless it may be possible in rare instances, through complex analysis and with outside information to ascertain from the data set the identity of particular persons. Considerable harm could ensue if this were done.

In order for the DCPC to provide a restricted dataset to you, it is necessary that you agree to the following provisions:

1. I will not use nor permit others to use the data in any way other than for statistical reporting and analysis;
2. I will not release nor permit others to release the data sets or any part of them to any person except with the written approval of DCPC;
3. I will not attempt to link nor permit others to link the data set with individually identifiable records from any other CDC or non-CDC data set;
4. I will not attempt to use the data sets or permit others to use them to learn the identity of any person or establishment included in any set; and
5. If the identity of any person or establishment should be discovered inadvertently, then
  - a) no use will be made of this knowledge,
  - b) the Director of the DCPC will be notified of the incident,
  - c) the information that would identify an individual or establishment will be safeguarded or destroyed as requested by DCPC, and
  - d) no one else will be informed of the discovered identity.

In addition, I will make every effort to release all statistical information in such a way as to avoid inadvertent disclosure. For example:

- No figure, including totals, should be less than 6 in tabulations, unless it is a tabulation routinely published by DCPC.
- No data on an identifiable case should be derivable through subtraction or other calculation from the combination of tables in a given publication.
- No data should permit disclosure when used in combination with other known data.

My signature indicates my agreement to comply with the above stated provisions with the knowledge that deliberately making a false statement regarding any matter within the jurisdiction of any department or agency of the Federal Government violates 18 USC 1001 and is punishable by a fine up to \$10,000 or up to five years in prison.

---

Signature

Date

Print or type name

Title

Organization

Mailing Address

Telephone

Fax

E-mail

Proposed use:

Please return completed form to:

Attention Mr. Joseph Rogers  
Division of Cancer Prevention and Control  
National Center for Chronic Disease Prevention and Health Promotion  
Centers for Disease Control and Prevention  
4770 Buford Hwy, N.E., Mailstop K-53  
Atlanta, GA 30341-3724  
Phone: (770) 488-4783  
Fax: (770) 488-4759

## Data Items for Restricted-Access Data Sets (RADS)

The restricted access data sets are individual case-specific data from the NPCR-CSS data set. The data items to be included are listed below.

Name	Status [NAACCR Data Item number listed in brackets]	Notes
<b>Demographic Data Items</b>		
Patient ID Number	[20]	
Address at Diagnosis—State	[80]	Only in sRADS
Address at Diagnosis—Census Region	Derived based upon [80]	
NPCR Race Recode	Derived based on [160], [161] and [192]	
Spanish/Hispanic Origin	[190]	
NHIA Derived Hispanic Origin	[191]	
Sex	[220]	
NPCR Age at Diagnosis	Derived based upon [230]	Age over 99 will be recoded.
NPCR Age Recode	Derived based upon [230]	
NPCR Birth Date	Derived based upon [240]	Only year will be provided; if age is over 99, then year of birth will be recoded.
<b>Cancer Identification Data Items</b>		
Sequence Number—Central	[380]	
NPCR Date of Diagnosis	Derived based upon [390]	Day of diagnosis will not be provided.
Primary Site	[400]	
Laterality	[410]	
Grade	[440]	
Diagnostic Confirmation	[490]	
Type of Reporting Source	[500]	
Histologic Type ICD-O-3	[522]	
Behavior Code ICD-O-3	[523]	
NPCR Behavior Recode for Analysis	Derived based upon [523]	
SEER Incidence Site Recode	Derived based upon [400] and [522]	
SEER Incidence Site Recode with mesothelioma and Kaposi sarcoma	Derived based upon [400] and [522]	
SEER International Classification of Childhood Cancer (ICCC) Recode	Derived based upon [400] and [523]	

Data Item	Status [NAACCR Data Item number listed in brackets]	Notes
<b>Stage/Prognostic Factors Data Items</b>		
SEER Summary Stage 2000	[759]	
SEER Summary Stage 1977	[760]	
CS Extension	[2810]	
CS Lymph Nodes	[2830]	
CS Mets at DX	[2850]	
CS Site-Specific Factor 1	[2935]	
CS Site-Specific Factor 3	[2900]	
CS Version 1 <sup>st</sup>	[2935]	
CS Version Latest	[2936]	
Derived SS2000	[3020]	
Derived SS2000—Flag	[3050]	
Derived SS1977	[3010]	
<b>Over-ride Flags</b>		
Over-ride Age/Site/Morph	[1990]	
Over-ride SeqNo/DxConf	[2000]	
Over-ride Site/Lat/Sequence Number	[2010]	
Over-ride Site/Type	[2030]	
Over-ride Histology	[2040]	
Over-ride Report Source	[2050]	
Over-ride Ill-define Site	[2060]	
Over-ride Leuk,Lymphoma	[2070]	
Over-ride Site/Behavior	[2071]	
Over-ride Site/Lat/Morph	[2074]	